Press release
Diabetic Retinopathy - Drug Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Adverum Biotechnologies Inc, Aerie Pharmaceuticals, Allergan, Amytrx T
"Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key -https://www.globalinsightservices.com/request-sample/GIS31255
Diabetic retinopathy is a censorious medical disorder that affects the eyes due to inefficient insulin level in the blood of the patient. A high sugar level in the blood causes blockage of the retina's small blood capillaries, impeding blood flow resulting in cloudy or blurred vision. There are two types of diabetic retinopathy non-proliferative diabetic retinopathy and proliferative diabetic retinopathy.
A high sugar level in the blood causes blockage of the retina's small blood capillaries and impairment to blood vessels of the light-sensitive tissue of the retina is the main cause of diabetic retinopathy.
Symptoms of diabetic retinopathy are blurred vision, dark or empty spots in the vision, fluctuating vision, poor colour identification and vision loss.
Diabetic retinopathy is diagnosed by a comprehensive dilated eye exam and Fluorescein angiography.
Diabetic retinopathy is treated by diet modifications and drugs like insulin vascular endothelial growth factor inhibitors and laser treatment, eye surgery.
Read more about Diabetic Retinopathy - Drug Pipeline Landscape, 2023 Insight here:https://www.globalinsightservices.com/reports/diabetic-retinopathy-drug-pipeline-landscape/
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Diabetic Retinopathy treatment such as KSI-301, LY-09004, RTH258 and others. Key players involved in the development of therapies to treat Diabetic Retinopathy are Bayer, Boehringer Ingelheim, F. Hoffmann-La Roche AG, Hengenix Biotech Inc, OcuTerra Therapeutics Inc and others. Seven drugs are under late-stage Phase III clinical trials and sixteen drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
In October 2022, OcuTerra published safety and biological activity data of OTT166 from phase 1b study in diabetic eye disease.
Report Highlights
Global Insight Service's, Diabetic Retinopathy - Drug Pipeline Landscape, 2023 report provides an overview of the Diabetic Retinopathy pipeline drugs. This report covers detailed insights on Diabetic Retinopathy drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Diabetic Retinopathy pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Buy your copy now: https://www.globalinsightservices.com/checkout/single_user/GIS31255
Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Retinopathy - Drug Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Adverum Biotechnologies Inc, Aerie Pharmaceuticals, Allergan, Amytrx T here
News-ID: 2948094 • Views: …
More Releases from Global insight services
Immuno Oncology Drugs Market Projected to Reach $634.1 Billion by 2034, Growing …
The Immuno Oncology Drugs Market is rapidly emerging as a transformative segment in the global healthcare industry. These drugs harness the body's immune system to identify and attack cancer cells, offering innovative treatment alternatives to traditional chemotherapy and radiation therapies. Immuno-oncology therapies include monoclonal antibodies, checkpoint inhibitors, cancer vaccines, and cell-based therapies such as CAR-T cells. The growth of this market is primarily driven by advancements in biotechnology, an improved…
GLP 1 Market Projected to Reach $221.8 Billion by 2034, Growing at 9% CAGR | Ove …
The GLP 1 Market is experiencing unprecedented growth, fueled by the rising prevalence of type 2 diabetes and obesity globally. GLP-1, or glucagon-like peptide-1 receptor agonists, represents a groundbreaking therapeutic class that improves insulin secretion, reduces glucagon production, and slows gastric emptying. These mechanisms not only enhance glycemic control but also support weight management, making GLP-1 therapies a preferred choice among healthcare providers and patients alike. Over the years, the…
Autonomous Bus Market to Expand to $11.6 Billion by 2034, Advancing at 18.8% CAG …
Market Overview
Autonomous Bus Market is revolutionizing the future of urban mobility through advanced automation technologies. Valued at $2.1 billion in 2024, the market is projected to reach $11.6 billion by 2034, expanding at a strong CAGR of 18.8%. This market focuses on the development and deployment of self-driving buses equipped with cutting-edge sensors, artificial intelligence, and vehicle-to-everything (V2X) communication systems. These buses are designed to improve road safety, enhance passenger…
Automotive Tire Market to Attain $976.7 Billion by 2034, Growing at 9.2% CAGR | …
Market Overview
Automotive Tire Market is experiencing remarkable growth as the industry embraces innovation, sustainability, and digital transformation. Valued at $406 billion in 2024, the market is projected to soar to $976.7 billion by 2034, reflecting a CAGR of 9.2%. This expansion is primarily driven by the surge in global vehicle production, growing consumer preference for durable and high-performance tires, and the increasing adoption of smart tire technologies. The Automotive Tire…
More Releases for Diabetic
Diabetic Socks Market Dynamics Shaped by Rising Diabetic Population - Persistenc …
The diabetic socks market is gaining significant traction worldwide, driven by the rising prevalence of diabetes and related complications such as diabetic neuropathy and foot ulcers. Designed specifically to cater to the needs of diabetic patients, these socks play a crucial role in foot protection by preventing blistering, reducing moisture accumulation, and providing cushioning to minimize the risk of ulcers. This article delves deeply into the diabetic socks market, exploring…
Leading Element Driving Change in the Diabetic Footwear Market in 2025: Rising D …
Which drivers are expected to have the greatest impact on the over the diabetic footwear market's growth?
The surge in people with diabetes will spur the expansion of the diabetic footwear market in the future. Diabetes, characterised by high blood sugar levels, is a long-term health issue. Diabetic footwear can prevent severe foot-related issues caused by diabetes and offer several advantages such as enhanced blood flow, ample space for the toes,…
Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report.
On the basis of…
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and…
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025.
To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282
Global Diabetic Socks Market: Factors Impacting the Market
The primary factors driving the growth of the global diabetic socks market are increasing…
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be…
